Exenatide: An incretin mimetic for the treatment of type 2 diabetes mellitus

Clinical Therapeutics

Volumn 28, Issue 5, 2006, Pages 652-665

  Iltz, Jason L ^a,b   Baker, Danial E ^a   Setter, Stephen M ^a,c   Keith Campbell, R ^d  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b CENTER FOR HEALTH STUDIES   (United States)

^c Elder Services   (United States)

^d WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

diabetes mellitus.; exenatide; exendin 4; GLP 1; glucagon like peptide 1; incretin mimetic; type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIBIOTIC AGENT; CHLORPROPAMIDE; DIGOXIN; DRUG ANTIBODY; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN; INSULIN; INSULIN GLARGINE; LISINOPRIL; MEGLITINIDE; METFORMIN; MEVINOLIN; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PLACEBO; SULFONYLUREA; TOLAZAMIDE; TOLBUTAMIDE; WARFARIN;

ANTIBODY PRODUCTION; AREA UNDER THE CURVE; ARTICLE; BONE DISEASE; BREAST MILK; CHRONOTHERAPY; CIRCADIAN RHYTHM; CIRCULATION; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETIC KETOACIDOSIS; DIARRHEA; DIET; DIET RESTRICTION; DIZZINESS; DOSE CALCULATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG MECHANISM; DRUG MEGADOSE; DRUG MILK LEVEL; DRUG POTENTIATION; DRUG RELEASE; DRUG SAFETY; DRUG STORAGE; DRUG TOLERABILITY; DRUG TRANSPORT; DYSPEPSIA; EXERCISE; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; GROWTH INHIBITION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INFORMATION RETRIEVAL; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN RESPONSE; INTESTINE; KIDNEY FAILURE; LIVER FAILURE; MAXIMUM PERMISSIBLE DOSE; MEAL; MEDICAL LITERATURE; MEDLINE; MOLECULAR MIMICRY; MONOTHERAPY; NAUSEA; NERVOUSNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT MONITORING; PLACENTA PERFUSION; PREGNANCY; REGULATORY MECHANISM; RISK BENEFIT ANALYSIS; SHORT COURSE THERAPY; SIDE EFFECT; STATISTICAL ANALYSIS; STEADY STATE; STOMACH EMPTYING; TERATOGENICITY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FASTING; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; METFORMIN; PEPTIDES; SULFONYLUREA COMPOUNDS; VENOMS;

EID: 33745970187     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.05.006     Document Type: Article

References (33)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet General Information and National Estimates on Diabetes in the United States, 2005 (2005), US Dept of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, Ga
2. Hogan P., Dall T., Nikolov P., and American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care 26 (2003) 917-932
3. Saydah S.H., Fradkin J., and Cowie C.C. Poor control of risk factors for vascu lar disease among adults with previously diagnosed diabetes. JAMA 29 (2004) 335-342
4. Nauck M.A., and Meier J.J. Glucagon-like peptide l and its derivatives in the treatment of diabetes. Regul Pept 128 (2005) 135-148
5. Baker D.E. Exenatide: Improves glycemic control in patients with type 2 diabetes mellitus. Adv Pharm 3 (2005) 14-22
6. Neilson L.L., and Baron A.D. Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. Curr Opin Investig Drugs 4 (2003) 401-405
7. Raufman J.P. Bioactive peptides from lizard venoms. Regal Pept 61 (1996) 1-18
8. Goke R., Fehmann H.C., Linn T., et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide and antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 268 (1993) 19650-19655
9. Habeck M. Diabetes treatments get sweet help from nature. Nat Med 9 (2003) 1228
10. Keating G.M. Exenatide. Drugs 65 (2005) 1681-1692
11. Drucker D.J. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26 (2003) 2929-2940
12. Exenatide injection (2005), Amylin Pharmaceuticals, Inc, San Diego, Calif
13. Degn K.B., Brock B., Juhl C.B., et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucosedependent insulin secretion and counterregulation during hypoglycemia. Diabetes 53 (2004) 2397-2403
14. Egan J.M., Cloccuet A.R., and Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: Comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 87 (2002) 1282-1290
15. Kolterman O.G., Buse J.B., Fineman M.S., et al. Synthetic exendin-4 (exenatide) significantly reduces post-prandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88 (2003) 3082-3089
16. Fehse F.C., Trautmann M., Holst J.J., et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 90 (2005) 5991-5997
17. Fineman M.S., Bicsak T.A., Shen L.Z., et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing mefformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 26 (2003) 2370-2377
18. Kolterman O.G., Kim D.D., Shen L., et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide i n patients with type 2 diabetes mellitus. Am. J Health Syst Pharm 62 (2005) 173-181
19. Blase E., Taylor K., Gao H., et al. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. J Clin Pharmacol 45 (2005) 570-577
20. Nielson L.L., Young A.A., and Parkes D.G. Pharmacology of exenatide (synthetic exendin-4): A potential therapeutic for improved glycemic control of type 2 diabetes. Regal Pept 117 (2004) 77-88
21. Gedulin B.R., Nikoulina S.E., Smith P.A., et al. Exenatide (exendin-4) improves insulin sensitivity and β-cell mass in insulin-resistant obese fa/fa Zucker rats independent ofglycemia and bodyweight. Endocrinology 146 (2005) 2069-2076
22. Szayna M., Doyle M.E., Betkey J.A., et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141 (2000) 1936-1941
23. Edwards C.M., Stanley S.A., Davis R., et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 281 (2001) E155-E161
24. DeFronzo R.A., Ratner R.E., Han J., et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 (2005) 1092-1100
25. Buse J.B., Henry R.R., Han J.,., et al., Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 (2004) 2628-2635
26. Kendall D.M., Riddle M.C., Rosenstock J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28 (2005) 1083-1091
27. Calara F., Taylor K., Han J., et al. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin Ther 27 (2005) 210-215
28. Kothare P.A., Soon D.K., Linnebjerg H., et al. Effect of exenatide on the steady-state pharmacokinetics of digoxin. J Clin Pharmacol 45 (2005) 1032-1037
29. Hiles R.A., Bawdon R.E., and Petrella E.M. Ex vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4). Hum Exp Toxicol 22 (2003) 623-628
30. Poon T., Nelson P., Shen L., et al. Exenatide improves glycemic control and reduces bodyweight in subjects with type 2 diabetes: A dose-ranging study. Diabetes Technol Ther 7 (2005) 467-477
31. Fineman M.S., Shen L.Z., Taylor K., et al. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 20 (2004) 411-417
32. Heine R.J., Van Gaal L.F., Johns D., et al., GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial. Ann Intern Med 143 (2005) 559-569
33. Byetta® P&T QUIK® Reports. July 2005. Available at: http://www. thomsonhc.com. Accessed March 14, 2006.